Download PDF
Semin intervent Radiol 2013; 30(02): 151-156
DOI: 10.1055/s-0033-1342956
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Lung Cancer Ablation: What Is the Evidence?

Thierry de Baere
1   Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, France
,
Geoffroy Farouil
1   Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, France
,
Frederic Deschamps
1   Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, France
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2013 (online)

Also available at
   Buy Article Permissions and Reprints
Zoom Image

Abstract

Percutaneous ablation of small non–small cell lung cancer (NSCLC) has been demonstrated to be both feasible and safe in nonsurgical candidates. Radiofrequency ablation (RFA), the most commonly used technique for ablation, has a reported rate of complete ablation of ~90%, with best results obtained in tumors <2 to 3 cm in diameter. The best reported 1-, 3-, and 5-year overall survival rates after RFA of NSCLC are 97.7%, 72.9%, and 55.7%, respectively. It is noteworthy that in most studies, cancer-specific survival is greater than overall survival due to severe comorbidities in patients treated with RFA for NSCLC. Aside from tumor size and tumor stage, these comorbidities are predictive of survival. Other ablation techniques such as microwave and irreversible electroporation may in the future prove to overcome some of the limitations of RFA, namely for large tumors or tumors close to large vessels. Stereotactic body radiation therapy has also been demonstrated to be highly efficacious in treating small lung tumors and will need to be compared with percutaneous ablation. This article reviews the current evidence regarding RFA for lung cancer.

Keywords

lung cancer - non–small cell lung cancer - radiofrequency ablation - interventional radiology